Stacy Lindborg, Ph.D. joined Brainstorm in June 2020 and serves as Co-Chief Executive Officer as of January 2023.  Dr. Lindborg is an experienced healthcare executive and globally recognized medical statistician with over 2 decades of multinational experience in R&D, regulatory, strategy development, analytics and big data.  Her experience includes senior roles at Eli Lilly & Company and Biogen.  At Biogen she was Vice President, Analytics and Data Science, where she built a world class Analytics and Data Sciences team, responsible for global data as well as statistical and epidemiological support for R&D and marketed products. She was active in guiding the firm’s long-term vision for growth through analytics and by stimulating innovative development platforms to increase productivity. Her team motivated novel analytic and development approaches, that contributed in material ways to products such as Spinraza® and Aducanumab®.  At Eli Lilly & Company, she held positions of increasing responsibility including Head of R&D strategy, where she was responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan.  In this role, she created seminal insights into R&D productivity by connecting individual drug program-based development decisions to portfolio risk practices, driving fundamental R&D decisions to increase number of drug launches. Additionally, she was Leader of Zyprexa Product Management in which she was responsible for R&D, Commercial and Manufacturing plans. She was accountable for driving market share through product differentiation, global registration and launching of an injectable form of Zyprexa, working through regulatory manufacturing inspections and 483 citations. Zyprexa had peak sales of $4.7 billion.

Dr. Lindborg holds a Ph.D. in statistics from Baylor University. She has been active in professional organizations across her career, holding numerous positions within the American Statistical Association and International Biometric Society, having been elected Fellow of the association in 2008. She serves on the Scientific Advisory Board of biotechnology and technology companies and on the board of directors of the Massachusetts Down Syndrome Congress.